Cognitive processes mediated by the hippocampus and cortex are influenced by estradiol (E 2 ); however, the mechanisms by which E 2 has these effects are not entirely clear. As such, studies were conducted to begin to address the role of actions at the b form of the intracellular estrogen receptor (ERb) for E 2 's cognitive effects in adult female mice. We investigated whether E 2 improved performance of wild type (WT) and ERb knockout (bERKO) mice in tasks considered to be mediated by the cortex and hippocampus, the object recognition and object placement tasks. WT and bERKO mice were ovariectomized (ovx) and E 2 (0.1 mg/kg), an ERb selective ER modulator (SERM), diarylpropionitrile (DPN; 0.1 mg/kg), or oil vehicle was administered to mice following training in these tasks. We hypothesized that if E 2 has mnemonic effects, in part, due to its actions at ERb, then WT mice administered E 2 or DPN would have improved performance compared to vehicle WT controls, which would not be different from bERKO mice administered vehicle, E 2 or DPN. Alternatively, activation of ERa (with E 2 , which is a ligand for both ERa and ERb) may produce opposing effects on cognition and/or the activation of ERa and ERb vs. either receptor isoform alone may produce a different pattern of effects. Results obtained supported the hypothesis that ERb activation is important for mnemonic effects. Ovx WT, but not bERKO, mice administered E 2 or DPN had a greater percentage of time exploring a novel object in the object recognition task and a displaced object in the object placement task. Thus, actions at ERb may be important for E 2 or SERMs to enhance cognitive performance of female mice in the object recognition and placement tasks.
Introduction
Steroid hormones, such as estradiol (E 2 ), can have trophic effects in the central nervous system. However, results of recent clinical trials suggest that E 2 -based replacement therapies are not beneficial to all women (Almeida et al., 2006; Espeland et al., 2004; LeBlanc, Janowsky, Chan, & Nelson, 2001; Shumaker et al., 2004; Yaffe, Sawaya, Lieberburg, & Grady, 1998) . These initial reports included findings from women seventy years old and older, who had been post-menopausal for an average of 20 years. More recent re-analyses of these data suggest that E 2 -based therapies can confer some benefit to women when treatment begins closer to the onset of menopause (reviewed
